Sun Pharma gets USFDA`s tentative nod for Strattera capsules
Mumbai: Sun Pharmaceutical Industries on Thursday said it has got tentative approval from the US drug regulator for its generic product Strattera used in the treatment of mental disorders.
The US Food and Drug Administration has approved Strattera
atomoxetine hydrochloride capsules, which is equivalent to
drug manufacturer Eli Lilly`s Strattera capsules, Sun Pharma
said in a filing to the Bombay Stock Exchange (BSE).
These capsules are available in seven strengths--10 mg,
18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the Mumbai-based
drug maker said.
The capsules, used in the treatment of attention deficit
hyperactivity disorder, have an annual sales of nearly USD 500
million in the US.
Shares of Sun Pharma today closed at Rs 1463.25, higher
by 0.78 per cent from its previous close on the BSE, whose
benchmark index--Sensex--fell by 344.02 points to close at
More from India
More from World
More from Sports
More from Entertaiment
- RJD strongman Shahabuddin brought to Delhi
- NSG now 'nine times' stronger; receives technological strength from 12 countries!
- UP elections in third phase; voting on 69 seats of 12 districts
- DNA: Today in History, 18th February, 2017
- Panel discussion over why SP government is backing Gayatri Prajapati
- 'BJP is winning by absolute majority in Uttar Pradesh Assembly elections'
- 7th Pay Commission: Allowances committee raises HRA to 30%?
- India can meet its energy requirements from Moon by 2030, says ISRO
- J&K: 26 soldiers martyred, 22 militants killed as Army steps up security in Valley
- Virat Kohli becomes first Indian sportsperson to sign Rs 100-crore endorsement deal